The HARTMANN GROUP continued its growth despite the difficult conditions in the health markets. Global sales revenues increased by 5.0 percent to EUR 1,263.8 million compared to the previous year.
Also in the third quarter of the fiscal year, the company was confronted with significant price pressures and lower reimbursement rates for medical products in the national health markets. Prices for raw materials, crude oil and transportation remained at a high level. Due to an unfavorable market environment, EBIT declined by 1.6 percent to EUR 78.9 million after nine months. The consolidated net income decreased by 5.5 percent to EUR 50.8 million.In the Wound Management segment, sales revenues were EUR 342.1 million as at September 30, 2011, an increase of 3.7 percent. HARTMANN recorded growth in all major product categories for professional wound care. The consumer-focused range in pharmacies was also increasingly well received by customers. In the Incontinence Management segment, HARTMANN recorded a sales increase of 2.2 percent to EUR 453.2 million as at the end of the third quarter of 2011. Two-piece systems, pads and fixation pants in particular contributed to the sales growth. MoliCare Mobile, the incontinence pants for mobile patients, was again the strongest growing product in this segment. The Infection Management segment continued its double-digit growth in the course of fiscal year 2011. Sales revenues rose by 13.2 percent to EUR 279.2 million as at September 30, 2011. Major growth drivers were the product categories of surgical sets, disinfectants and gloves.The share of the medical core segments in total sales was 85.0 percent as at September 30, 2011. Other Group Activities recorded sales revenues of EUR 189.2 million in the first nine months of the fiscal year, an increase of 2.9 percent compared to the previous year. The CMC Group and the Kneipp Group contributed to this growth.
Growth and profitability continue to remain the top priority of the HARTMANN GROUP in fiscal year 2011. With a product portfolio based on customer needs and added-value services the company is well positioned as an established branded medical device company to be the preferred partner for an increasing number of customers worldwide. However, HARTMANN continues to expect volatile raw material and logistics costs still remaining at a high level, and strongly fluctuating exchange rates. The continued debate regarding appropriate measures to solve the debt crisis in various national economies makes it additionally difficult to give a concrete forecast on the market conditions for the HARTMANN GROUP. In view of the efforts to consolidate national budgets, the company expects a further increase of price pressure from customers on an international scale. CEO Dr. Rinaldo Riguzzi: “Under our Group-wide Cost Reduction and Stabilization of Results program, we have been reviewing all costs and are implementing a large number of measures as planned. In addition, we succeeded in raising market selling prices. Considering all relevant factors, we aim for a consolidated operating profit in 2011 at last year's record level.”